Discontinuing Statins in Older Adults without Cardiovascular Disease
Source: View publication →
In multimorbid adults 70 years and older taking statins for primary prevention, discontinuing therapy was noninferior to continuation based on event-free survival time at 2 years, although absolute event rates were numerically higher upon discontinuation.
Key Findings
Study Design
Study Limitations
Clinical Significance
While statin discontinuation formally met the trial's statistical noninferiority endpoint, the higher incidence of myocardial infarction, stroke, and death in the discontinuation group (12.7% vs. 9.2%) indicates that stopping statins is not entirely risk-free. These findings suggest that deprescribing statins in older adults should be approached cautiously through shared decision-making, balancing the desire to reduce polypharmacy against a discernible increase in cardiovascular risk.
Historical Context
With an aging population and increasing rates of multimorbidity, polypharmacy has become a significant clinical challenge. Statins are frequently prescribed for primary prevention in older adults, but their benefit in patients over 70 without known cardiovascular disease has been debated. Prior to the STREAM trial, robust randomized data comparing continuation versus discontinuation of statin therapy in this specific population were lacking, leading to variable clinical practices regarding deprescribing.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of statins, and what is the fundamental difference in clinical reasoning between prescribing them for primary versus secondary cardiovascular prevention in older adults?
Key Response
Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, leading to upregulation of hepatic LDL receptors. Primary prevention aims to prevent a first cardiovascular event, where the absolute risk and thus absolute benefit are lower compared to secondary prevention which targets patients with established disease. This distinction is crucial when weighing the risks of polypharmacy and side effects against potential benefits in multimorbid older adults.
A 75-year-old patient with hypertension, osteoarthritis, and mild cognitive impairment asks if they can stop their atorvastatin, which they take for primary prevention. Based on this study, how should you counsel them regarding the risks and benefits of deprescribing?
Key Response
Residents must balance trial data with patient-centered care. Counsel the patient that discontinuing the statin was shown to be noninferior to continuing for overall event-free survival over 2 years in similar multimorbid older adults, which could reduce pill burden and side effects. However, they should also be informed that the absolute rate of cardiovascular events was numerically slightly higher when stopped, requiring a shared decision-making discussion prioritizing their current quality of life versus a small long-term cardiovascular risk.
The study demonstrates noninferiority for event-free survival at 2 years when discontinuing statins in primary prevention, despite a numerically higher cardiovascular event rate. How does the competing risk of non-cardiovascular mortality in multimorbid older adults impact the interpretation of this composite endpoint?
Key Response
In geriatric cardiology, competing risks are paramount. A 2-year event-free survival endpoint includes all-cause mortality and cardiovascular events. In multimorbid patients over 70, non-cardiovascular mortality often vastly outpaces cardiovascular mortality. Therefore, the noninferiority of deprescribing might be driven by the high background rate of non-cardiovascular deaths, diluting the impact of a slightly higher cardiovascular event rate. Fellows must recognize that statins do not alter non-CV competing risks, making deprescribing a valid strategy.
How can we practically integrate the concept of 'time-to-benefit' with the findings of this trial when teaching trainees about medication rationalization in geriatric populations?
Key Response
Attendings should emphasize the time-to-benefit framework. Statins for primary prevention typically require 2 to 5 years to demonstrate a mortality or significant morbidity benefit. If a multimorbid older patient has a life expectancy of less than this time horizon, continuing a preventive medication is clinically illogical. This trial validates that over a 2-year period, stopping the statin is safe and noninferior, providing a strong evidence-based teaching tool to help trainees overcome the psychological barrier of deprescribing.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
How does the choice of the noninferiority margin and a relatively short 2-year follow-up period uniquely complicate the statistical interpretation of primary prevention deprescribing trials, and how could future adaptive trial designs address this?
Key Response
Primary prevention events take time to accrue. A 2-year follow-up might be insufficiently long to capture the divergence in cardiovascular event curves, biasing the study toward a conclusion of noninferiority (a type II error for superiority of continuation). Furthermore, wide noninferiority margins in the setting of low overall event rates can easily be met even if a true, biologically significant risk exists. Future designs could use longer-term pragmatic follow-up or adaptive margins based on the observed accrual of competing non-cardiovascular events.
Given that cardiovascular event rates were numerically higher in the discontinuation group, how would you critically evaluate whether the composite primary endpoint masked important subgroups who suffered harm from deprescribing, and what sensitivity analyses would you demand prior to publication?
Key Response
As an editor, the concern is that a composite endpoint in a highly multimorbid population might obscure specific, predictable cardiovascular harms. A rigorous review would demand sensitivity analyses isolating cardiovascular mortality and non-fatal MI/stroke, as well as subgroup analyses based on baseline LDL, coronary calcium scores, and frailty indices, to ensure the noninferiority is not just a statistical artifact of overwhelming non-CV mortality in the sickest patients.
Current ACC/AHA guidelines provide a Class IIb recommendation for initiating statins for primary prevention in adults over 75, but offer limited guidance on deprescribing. How should this trial's findings be translated into a formal guideline recommendation for discontinuing statin therapy in multimorbid older adults?
Key Response
The guidelines currently emphasize shared decision-making for initiation but lack robust RCT data for discontinuation. This trial provides Level B-R (Randomized) evidence to support a new Class IIa or IIb recommendation explicitly stating that in multimorbid adults over 70 taking statins for primary prevention, discontinuing therapy is reasonable to reduce pill burden, particularly when life expectancy is limited. The committee must weigh the noninferiority of overall survival against the numerically higher CV events, framing the recommendation around life expectancy and patient preferences.
Clinical Landscape
Noteworthy Related Trials
PROSPER Trial
Tested
Pravastatin 40mg daily
Population
Older adults (70-82 years) with or at high risk for vascular disease
Comparator
Placebo
Endpoint
Composite of coronary death, non-fatal MI, and fatal or non-fatal stroke
JUPITER Trial
Tested
Rosuvastatin 20mg daily
Population
Healthy older adults with normal LDL-C but elevated hsCRP
Comparator
Placebo
Endpoint
First major cardiovascular event
Statin Discontinuation Trial
Tested
Discontinuation of statin therapy
Population
Patients with advanced, life-limiting illness
Comparator
Continuation of statin therapy
Endpoint
Death within 60 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis